HMI-1a3 | CAS#unknown | Protein kinase C partial agonist

MedKoo Cat#: 466142 | Name: HMI-1a3

Description:

WARNING: This product is for research use only, not for human or veterinary use.

HMI-1a3 is a protein kinase C partial agonist, targeting the C1 domain, inhibiting cell proliferation, decreasing cell viability and inducing an apoptotic response.

Chemical Structure

HMI-1a3

CAS#unknown

Theoretical Analysis

MedKoo Cat#: 466142

Name: HMI-1a3

CAS#: unknown

Chemical Formula: C25H18F6O5

Exact Mass: 512.1058

Molecular Weight: 512.40

Elemental Analysis: C, 58.60; H, 3.54; F, 22.25; O, 15.61

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

HMI-1a3; HMI1a3; HMI 1a3;

IUPAC/Chemical Name

bis(3-(trifluoromethyl)benzyl) 5-(hydroxymethyl)isophthalate

InChi Key

OLYSKMGKJANIPC-UHFFFAOYSA-N

InChi Code

InChI=1S/C25H18F6O5/c26-24(27,28)20-5-1-3-15(9-20)13-35-22(33)18-7-17(12-32)8-19(11-18)23(34)36-14-16-4-2-6-21(10-16)25(29,30)31/h1-11,32H,12-14H2

SMILES Code

FC(F)(F)C1=CC=CC(COC(C2=CC(CO)=CC(C(OCC3=CC(C(F)(F)F)=CC=C3)=O)=C2)=O)=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 512.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tarvainen I, Nunn RC, Tuominen RK, Jäntti MH, Talman V. Protein Kinase A-Mediated Effects of Protein Kinase C Partial Agonist 5-(Hydroxymethyl)Isophthalate 1a3 in Colorectal Cancer Cells. J Pharmacol Exp Ther. 2022 Jan;380(1):54-62. doi: 10.1124/jpet.121.000848. Epub 2021 Oct 25. PMID: 34697230. 2: Lautala S, Provenzani R, Koivuniemi A, Kulig W, Talman V, Róg T, Tuominen RK, Yli-Kauhaluoma J, Bunker A. Rigorous Computational Study Reveals What Docking Overlooks: Double Trouble from Membrane Association in Protein Kinase C Modulators. J Chem Inf Model. 2020 Nov 23;60(11):5624-5633. doi: 10.1021/acs.jcim.0c00624. Epub 2020 Sep 21. PMID: 32915560. 3: Sarajärvi T, Jäntti M, Paldanius KMA, Natunen T, Wu JC, Mäkinen P, Tarvainen I, Tuominen RK, Talman V, Hiltunen M. Protein kinase C -activating isophthalate derivatives mitigate Alzheimer's disease-related cellular alterations. Neuropharmacology. 2018 Oct;141:76-88. doi: 10.1016/j.neuropharm.2018.08.020. Epub 2018 Aug 21. PMID: 30138694. 4: Jäntti MH, Talman V, Räsänen K, Tarvainen I, Koistinen H, Tuominen RK. Anticancer activity of the protein kinase C modulator HMI-1a3 in 2D and 3D cell culture models of androgen-responsive and androgen-unresponsive prostate cancer. FEBS Open Bio. 2018 Apr 17;8(5):817-828. doi: 10.1002/2211-5463.12419. PMID: 29744295; PMCID: PMC5929934. 5: Talman V, Provenzani R, Boije af Gennäs G, Tuominen RK, Yli-Kauhaluoma J. C1 domain-targeted isophthalates as protein kinase C modulators: structure-based design, structure-activity relationships and biological activities. Biochem Soc Trans. 2014 Dec;42(6):1543-9. doi: 10.1042/BST20140181. PMID: 25399568. 6: Talman V, Gateva G, Ahti M, Ekokoski E, Lappalainen P, Tuominen RK. Evidence for a role of MRCK in mediating HeLa cell elongation induced by the C1 domain ligand HMI-1a3. Eur J Pharm Sci. 2014 May 13;55:46-57. doi: 10.1016/j.ejps.2014.01.002. Epub 2014 Jan 29. PMID: 24486483. 7: Talman V, Amadio M, Osera C, Sorvari S, Boije Af Gennäs G, Yli-Kauhaluoma J, Rossi D, Govoni S, Collina S, Ekokoski E, Tuominen RK, Pascale A. The C1 domain- targeted isophthalate derivative HMI-1b11 promotes neurite outgrowth and GAP-43 expression through PKCα activation in SH-SY5Y cells. Pharmacol Res. 2013 Jul;73:44-54. doi: 10.1016/j.phrs.2013.04.008. Epub 2013 May 3. PMID: 23643828. 8: Talman V, Tuominen RK, Boije af Gennäs G, Yli-Kauhaluoma J, Ekokoski E. C1 Domain-targeted isophthalate derivatives induce cell elongation and cell cycle arrest in HeLa cells. PLoS One. 2011;6(5):e20053. doi: 10.1371/journal.pone.0020053. Epub 2011 May 23. Erratum in: PLoS One. 2011;6(6). doi:0.1371/annotation/7608bd2a-e319-47fd-ae20-478ee2875e27. Gennäs, Gustav Boije Af [corrected to Boije af Gennäs, Gustav]. PMID: 21629792; PMCID: PMC3100349.